What the FDA labels say about taking them together
Brodalumab and cyclosporine
Brodalumab's FDA label of May 28, 2026 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name brodalumab. The brodalumab label: “… monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate.”
Check it at the source: the brodalumab FDA label on DailyMed (effective May 28, 2026, Bausch Health US LLC); the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation).
What does the brodalumab label say about cyclosporine?
Brodalumab label, drug interactionsTherefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Siliq), BLA761032 (Valeant Luxembourg), as published by Bausch Health US LLC, effective May 28, 2026 (SPL set 1a550c33-456a-4833-814e-8591aea7c688), via openFDA; the full label on DailyMed
What does the cyclosporine label say about brodalumab?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name brodalumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Brodalumab | Cyclosporine | |
|---|---|---|
| Labeled for | Psoriasis | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $1.04 per unit 0.05% eye emulsion |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once